Loading
Life sciences · Journal article
Medicine · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Immune-related pancreatitis is a rare but clinically significant adverse event associated with immune checkpoint inhibitor therapy. Early recognition and appropriate management are essential to prevent potentially serious outcomes. Herein, we report a case of suspected immune-related pancreatitis during nivolumab-based immunotherapy for metastatic gastric cancer. Case presentation: An 82-year-old female patient, post-gastrectomy for gastric cancer with subsequent cerebral metastases, multiple leptomeningeal metastases, subcutaneous metastases, and retroperitoneal lymph node metastases, received “nivolumab + apatinib” therapy for 4 cycles. On the second day of the fourth cycle of treatment, the patient developed mild epigastric pain, acid regurgitation, and elevated pancreatic enzyme levels, suggestive of immune-related pancreatitis. Alternative etiologies, including biliary disease, alcohol use, and hypertriglyceridemia, were excluded. The patient was classified as Grade 1 according to the Common Terminology Criteria for Adverse Events v5.0 and was managed with fasting, parenteral nutrition, octreotide, enzyme inhibition, and electrolyte balance adjustment. Pancreatic enzyme levels normalized, and symptoms resolved. Nivolumab and apatinib were subsequently withheld. Conclusion: This case highlights that immune-related pancreatitis may present with only mild abdominal symptoms despite marked pancreatic enzyme elevation during immune checkpoint inhibitor therapy. Clinicians should maintain a high index of suspicion for pancreatic immune-related adverse events, even in the absence of typical imaging findings, and systematically exclude alternative causes to ensure timely and appropriate management.